

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

Poster Number	Title	First Name	Last Name	Affiliation
P001	Synthesis and co-crystal structure of an oligonucleotide inhibitor bound to the catalytically active APOBEC3G-CTD deaminase	Adam	Hedger	RTI, University of Massachusetts Chan Medical School
P002	An in vivo splice reporter platform to monitor real-time target engagement in the CNS	Akiko	Wagatsuma	Biogen
P003	The key role of a rabbit anti-phosphorothioate polyclonal antibody (pAb) in the detection of naked ASO and Oligonucleotide Transport Vehicle (OTV).	Alexander	Stergioulis	Denali
P004	Nucleic acid probes as biorecognition molecules for cancer detection	Alien	Balian	Linköping University
P005	Targeting the lncRNA SMILR Using siRNA for Therapeutic Intervention in Vein Graft Failure	Anna	Malinowska	MRC/UKRI Nucleic Acid Therapy Accelerator (NATA), Research Complex at Harwell
P006	Identification of heart and skeletal muscle homing peptides to improve the uptake of phosphorodiamidate morpholino oligomers (PMOs) for Duchenne Muscular Dystrophy therapy	Anne-Fleur	Schneider	Leiden University Medical Centre, Dept. of Human Genetics
P007	Personalized antisense oligonucleotide approach for a beta propeller protein-associated neurodegeneration patient	Anouk	Spruit	Dutch Center for RNA Therapeutics
P008	WITHDRAWN			
P009	WITHDRAWN			
P010	RNA editing by recruiting endogenous ADAR using long RNAs to correct glycine substitutions in COL6-RD	Astrid	Brull	National Institutes of Health
P011	Characterization of AML-specific DNA aptamers	Bahareh	Hosseinpour	Carleton University

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P012	Thiomorpholino Oligonucleotide (TMOs) synthesis and scale-up close to the DNA synthesis efficacy	Balazs	Schafer	Biochemistry Department University of Colorado Boulder
P013	Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics	Brendan	Finicle	University of California, Irvine
P014	A novel RNA therapy for accelerating healing of diabetic foot ulcers.	Brian	Johnston	SomaGenics
P015	Mono-specific and multi-specific aptamers: distinct mechanisms driven by molecular design	Brian	Thomas	University of Missouri School of Medicine
P016	Unlocking the potential of oligonucleotide therapeutic candidates through enhanced delivery.	Brijesh	Garg	PepGen
P017	Towards next generation antisense oligonucleotides – mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides	Brooke	Anderson	Ionis Pharmaceuticals
P018	Enhancing ADAR Editing At Disfavored Sites	Agya	Karki	UC Davis
P019	BROTHERSTM platform: overcoming toxicity using a novel antisense architecture	Chisato	Terada	Nagasaki University Graduate School of Biomedical Sciences
P020	National Institute of Neurological Disorders and Stroke's Ultra-Rare Gene-based Therapy (URGenT) Network	Chris	Boshoff	National Institute of Neurological Disorders and Stroke
P021	Insights Into the Mechanism and Function of Oligonucleotide Cas9 Inhibitors	Christopher	Barkau	Southern Illinois University School of Medicine
P022	Oligonucleotide-Based Telomere Disruptor for Prostate Cancer Immunotherapy	Chunsong	Yu	Beckman Research Institute of City of Hope
P023	Prioritization of the development of exon skipping therapy for epidermolysis bullosa	Cisse	Vermeer	UMCG

18th Annual Meeting of the Oligonucleotide Therapeutics Society

POSTER INDEX

P024	The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake and nephrotoxic liability of Antisense Oligonucleotide drug molecules.	Colin	Brown	Newcells Biotech
P025	Upregulation of SerpinG1 for treatment of hereditary angioedema using RNA actuators	Cynthia	Smith	CAMP4 Therapeutics
P026	Engineered Peptide Nucleic Acids to Drug the Genome™: A New Therapeutic Modality and Potential Best-in-Class Solutions for Huntington's Disease (HD) and Myotonic Dystrophy Type 1 (DM1)	Dani	Stoltzfus	NeuBase Therapeutics
P027	ASO-RNA hybridization and cleavage at single-molecule resolution as a function of target mismatches	Daniel	Berard	ScopeSys
P028	Development of anticancer RNA therapeutics with dual-targeting siRNA that silences ubiquitin family members and leads to cytotoxicity	David	Azorsa	Systems Oncology
P029	RNA aptamer targets lung cancer harboring EGFR activating mutations	David	Porciani	University of Missouri
P030	Evaluation of the role of epigenetic modifications in RNAi: Synthesis, Biophysical Properties, Nuclease Resistance, and RNAi Activity of siRNAs Containing 2'-Modified N6-Methyl Adenosine (m6A) and N6-Alkyl	Dhrubajyoti	Datta	Alnylam Pharmaceuticals
P031	Quantitation of Ago2-associated siRNA by Peptide Nucleic Acid (PNA) Hybridization Assay for RISC Loading Profiling	Di	Ma	Arrowhead Pharmaceuticals, Inc.
P032	WITHDRAWN			
P033	Base and Prime Editing in Inherited Retinal Diseases	Dong Hyun	Jo	Seoul National University College of Medicine
P034	Splice interventions for Parkinson's disease patients arising from PARK2 mutations	Dunhui	Li	Murdoch University
P035	Understanding the Stabilin receptor mediated endosomal escape mechanism of Phosphorothionate Antisense oligonucleotide (PS-ASOs)	Ekta	Pandey	University of Nebraska Lincoln

18th Annual Meeting of the Oligonucleotide Therapeutics Society

POSTER INDEX

P036	Lipid nanoparticle formulation enhances gene silencing, immunostimulatory properties and in vivo efficacy of CpG-STAT3siRNA against human B cell lymphoma	Elaine	Kang	City of Hope
P037	Efficacy and Tolerability of GLP-1 Conjugated ASOs Targeting the Beta Cell	Elaine	Pirie	Ionis Pharmaceuticals
P038	A role for bulges in predicting and interpreting siRNA off-target interactions	Eliot	Morrison	Silence Therapeutics
P039	Controlled, Template-Independent, Enzymatic Synthesis of RNA Oligonucleotides	Ella	Meyer	Department of Genetics, Harvard Medical School
P040	Enhancement of Antisense Oligomer Cell Penetration in Retinal Layers Using a Modular Cell Penetrating Peptide Platform	Emily	Woodward	PYC Therapeutics
P041	Intron-targeted antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects	Feng	Wang	UMass Chan Medical School
P042	Oligonucleotide enhancing compound increases tricyclo-DNA mediated exon-skipping efficacy in the mdx mouse model	Flavien	Bizot	Université Paris-Saclay
P043	Subcellular characterization of lipid nanoparticle mediated siRNA delivery	Hampus	Hedlund	Lund University, Department of Clinical Sciences Lund
P044	Development of an siRNA screening tool based on double-stranded RNA binding proteins	Hannah	Rose	Janssen R&D
P045	Peptide-based siRNA delivery platform in anti-cancer applications	Hua	Pan	Washington University School of Medicine
P046	Investigating corrole molecules for imaging and photodynamic siRNA therapeutics.	Ifrodet	Giorgees	Ontario Tech University
P047	Leveraging cell-type specific information to develop oligonucleotide therapeutics in the lung for the treatment of asthma	Io Long	Chan	University of Massachusetts Chan Medical School

18th Annual Meeting of the Oligonucleotide Therapeutics Society

POSTER INDEX

P048	Peptide conjugated anti-miRs rescue Myotonic Dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression	Irene	González-Martínez	University Research Institute for Biotechnology and Biomedicine
P049	Modulation of TLR9-stimulatory potential of oligonucleotides by cytosine methylation and LNA-modification is context dependent	Irene	Riera Tur	Secarna Pharmaceuticals GmbH & Co. KG
P050	Assessing efficacy and safety of delivery of different chemically modified antisense oligonucleotides to the eye	Irene	Vázquez-Domínguez	Department of Human Genetics, Radboud university medical center (Radboudumc)
P051	Development of Orthogonal and Multidirectional Gamma Peptide Nucleic Acids and their Applications	Isha	Dhami	Carnegie Mellon University
P052	Effect of stereochemistry and backbone chemistry on AIMer RNA editing efficiency	Jack	Godfrey	Wave Life Sciences
P053	Synergistic gene upregulation by RNA-targeting oligonucleotides with different mechanisms of action	Jack	Stahl	Center for Therapeutic Innovation, University of Miami Miller School of Medicine
P054	GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes	Jack	Wei	Sirnaomics, Inc.
P055	Mechanochemistry: Reducing the Solvent Footprint of Oligonucleotide Synthesis	James	Thorpe	McGill University
P056	Green-Light Activatable Phosphoramidites for Efficient Gene Regulation	Janik	Kaufmann	Goethe University
P057	Design and Characterization of Self Assembled Spherical Nucleic Acids for Gene Silencing	Jathavan	Asohan	Department of Chemistry, McGill University
P058	Synthesis of stereopure chimeric oligonucleotides containing PN and PS backbone: A systematic evaluation of chiral auxiliaries	Jayakanthan	Kumarasamy	Wave Life Sciences
P059	Oligo-PROTAC Strategy for Cell-Selective and Targeted Degradation of Activated STAT3	Jeremy	Hall	City of Hope

18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX

P060	Splice-switching Antisense Oligonucleotide Drug Discovery for CLN3 Batten Disease	Jessica	Centa	Chicago Medical School, Rosalind Franklin University of Medicine and Science
P061	A dual-targeting di-valent siRNA induces effective and potent CNS silencing of multiple targets	Jillian	Belgrad	RNA Therapeutics Institute, University of Massachusetts Chan Medical School
P062	Chemical Engineering of siRNA Scaffold with Enhanced SNP-based Allele Specific Gene Silencing	Jillian	Caiazza	RNA Therapeutics Institute, UMass Chan Medical School
P063	Splice-switching Oligonucleotide Targeting SLC25A13-PE5 as Therapeutic Candidate for Citrin Deficiency	Jin Rong	Ow	Agency for Science, Technology and Research (A*STAR)
P064	Tracking subcellular localization of siRNA after cytosolic entry	Johanna	Johansson	Lund University, Department of Clinical Sciences
P065	The role of nucleotide-amino acid π -stacking interactions in the photo cross-linking of RNA-protein complexes.	Jonathan	Hall	ETH Zurich
P066	Impact of chemistry and route of administration on siRNA delivery to the CNS	Julia	Alterman	UMass Chan Medical School
P067	Investigating GalNAc-siRNA Mediated Knockdown of Fas on Ischemia-Reperfusion Injury During the Liver Transplantation Process	Julianna	Buchwald	RNA Therapeutics Institute, UMass Chan Medical School
P068	ASO-mediated alternative splicing of MuSK as a therapeutic target for promoting adult hippocampal neurogenesis in neurodegenerative and neuropsychiatric disease	Justin	Fallon	Brown University
P069	Turning Down the Noise: Exploration and Exploitation of Cryptic Splicing	Kaitlyn	Brokaw	UMass Chan Medical School, RNA Therapeutics Institute
P070	Nanoparticle Single-Cell Multiomic Readouts Reveal that Cell Heterogeneity Influences Lipid Nanoparticle-Mediated mRNA Delivery	Kalina	Paunovska	Nava Therapeutics
P071	Therapeutic targeting of mutant p53 using mutation-specific siRNAs	Kanaga	Sabapathy	National Cancer Centre Singapore

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P072	Comparing Radiolabeled ASO Biodistribution Between Rats and NHPs	Kate	Park	Biogen
P073	RIG-I like Receptor Activation by mRNA Incorporating Modified Nucleosides	Katharina	Maser	University Hospital Bonn
P074	An in vitro model of the Kidney Glomerulus for Antisense Oligonucleotide Toxicity Screening	Kathryn	Garner	Newcells Biotech
P075	Therapeutic efficacy of microRNA and immunoadjuvant combination therapy for tumors	Kazuki	Sumiya	The University of Kitakyusyu
P076	Enzymatic synthesis of oligonucleotides with 2'-MOE modification	Kenta	Ishida	Graduate School of Pharmaceutical Sciences, Osaka University
P077	Synthesis and properties of oligonucleotides including a 2',4'-methylthioimidate bridged nucleic acid.	Kosuke	Miyata	Graduate School of Pharmaceutical Sciences, Osaka University
P078	Acute neurotoxicity by antisense oligonucleotides via CSF-route mediated by change of intracellular calcium level	Kotaro	Yoshioka	Department of Neurology, Tokyo Medical and Dental University
P079	Knock Down of TUBB6 Using Antisense Oligonucleotides	Kristin	Ha	Sarepta Therapeutics
P080	Tumor immune activation through intracellular hairpin DNA assembly	Kunihiko	Morihiro	The University of Tokyo
P081	Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression	Leo	Qian	Entrada Therapeutics
P082	Transporting ASOs across the BBB using TfR receptor mediated transcytosis	Lizanne	Nilewski	Denali Therapeutics
P083	Structure- "neurotoxicity" correlation in antisense oligonucleotides targeting central nervous system	Maho	Katsuyama	Department of Neurology, Tokyo Medical and Dental University

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P084	WITHDRAWN			
P085	TL-532, a novel rationally designed Toll-like receptor 3 agonist, induces tumor-specific apoptosis, immune stimulation, life-long anti-tumor autovaccination, and reverses resistance to immune checkpoint inhibitors	Marc	BONNIN	TOLLYS
P086	Targeted delivery of microRNAs OligoNucleotide Therapeutics to Ovarian Cancer cells and their tumor microenvironment for the treatment of human Ovarian Cancer	MARC	THIBONNIER	AptamiR Therapeutics, Inc.
P087	Patient-Specific Antisense Oligonucleotide Promotes Normal Splicing to Compensate for Loss of a Splicing Enhancer in PMM2-CDG	Margot	Cousin	Center for Individualized Medicine, Mayo Clinic
P088	Patient and variant stratification for personalized antisense oligonucleotide treatments	Marlen	Lauffer	Leiden University Medical Center
P089	Development of multi-targeting immunomodulatory SeekR™ RNA therapeutics to overcome resistance to immune checkpoint blockade	Marvin	O'Ketch	Systems Oncology
P090	New Design of Peptide Nucleic Acids Recognizing Double-Stranded DNA	Masanari	Shibata	Nagoya Univeraity
P091	SiRNAs with Neutral Phosphate Triester Hydrocarbon Tails Exhibit Carrier-Free Gene Silencing Activity	Matthew	Hammill	Ontario Tech University
P092	Effects of controlled S-alkylation of phosphorothioate-ASO on the therapeutic index	Md Ariful	Islam	Graduate School of Pharmaceutical Sciences, Osaka University
P093	Non-clinical and early clinical progress with STK-001, a potential disease modifying therapy for Dravet Syndrome	Meena	Meena	Stoke Therapeutics.com
P094	Validated method for siRNA Quantification using Stem-Loop Reverse Transcription Droplet Digital Polymerase Chain Reaction sufficient for regulatory filing	Megan	Turski	Takeda Development Center Americas
P095	A Novel RNAi-mediated Rheostat for Dynamic Control of AAV Delivered Transgenes	Megha	Subramanian	Alnylam Pharmaceuticals

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P096	Peptide-conjugated phosphorodiamidate morpholino oligomers for the treatment of Late-Onset Pompe Disease	Meghan	Ahern	Sarepta Therapeutics
P097	RNA therapy with TfR aptamer enhanced blood-brain barrier penetration for brain metastasis from Triple-negative Breast Cancer	Minsun	Song	Beckman Research Institute of City of Hope
P098	Hardware-accelerated edit distance analysis enables genome-wide identification of oligonucleotide off-target effects	Mitchell	Ledwith	La Jolla Labs
P099	The therapeutic use of small activating RNAs in cancer patients. Activating key transcription factors may be the driver to increasing response rates to conventional anti-cancer drugs.	Nagy	Habib	MiNA Therapeutics
P100	Antisense strategies against repeat RNA toxicity in myotonic dystrophy	Najoua	El Boujnouni	Radboud Institute for Molecular Life Sciences
P101	Stereopure oligonucleotides incorporating phosphoryl guanidine backbone increase durability of gene silencing by RNAi	Naoki	Iwamoto	Wave Life Sciences
P102	Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics and Investigation of their Sequence-Penetration Relationship	Nefeli	Batistatou	Tufts University
P103	Scale-Up Capsule Filtration of Oligonucleotide Solutions for cGMP Use	Nicole	Laliberte	LGC Biosearch Technologies
P104	ATDBio (now part of Biotage): your partner for highly complex oligonucleotides for any application	Nicolo	Zuin Fantoni	ATDBio (Biotage)
P105	Enzymatic RNA Synthesis	Nilesh	Karalkar	Foundation for Applied Molecular Evolution
P106	Knock down of uromodulin using antisense oligonucleotides as a potential treatment for Autosomal Dominant Tubulointerstitial Kidney Disease	Nino	Jungels	Sarepta Therapeutics
P107	Exploration of the intracellular aptamer that inhibits aggregation of ALS-associated protein FUS	Nobuaki	Kuroiwa	Department of Neurology, Tokyo Medical and Dental University

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P108	Therapeutic application of engineered U1 snRNAs in retinopathies	Paolo	Pigini	Agency for Science, Technology and Research (A*STAR)
P109	AS-202, a 5-10-5 MOE gapmer targeting the lipid kinase PIKFYVE as a treatment for sporadic ALS and FTD: Safety and target engagement in murine and nonhuman primate studies	Peter	Sazani	Acurastem
P110	Molecular Guidance Systems (MGS) as a Versatile Vehicles for cell-specific targeted delivery of siRNA bioconjugates.	Priyanka	Shukla	SRI International
P111	Divalent Cation Buffering of Oligonucleotides Prevents siRNA-induced Neurotoxicity	Rachael	Miller	UMass Chan Medical School
P112	High-throughput in vitro assay to measure ASO-induced modulation of neural activity	Rafael	Renteria	Creyon Bio
P113	Journey of DART: Aspiring to achieve Total Annihilation of Duchenne Muscular Dystrophy	Ravdeep	Anand	Dystrophy Annihilation Research Trust
P114	Investigating the effect of DMD non-sequential splicing on exon skipping strategies	Remko	Goossens	Leiden University Medical Center, Department of Human Genetics
P115	ION224, A GalNAc3 Ligand Conjugated Antisense Oligonucleotide Targeting Diacylglycerol O-Acyltransferase Isoform 2 enzyme mRNA Does Not Prolong QTc Intervals in Healthy Volunteers	Richard	Geary	Ionis Pharmaceuticals
P116	DG9 peptide-conjugated morpholino crosses the blood-brain barrier and rescues phenotype in SMA model mice	Rika	Maruyama	University of Alberta
P117	Development of Analytical Methods for Oligonucleotide Therapeutics Impurities	Risa	Suzuki	Shimadzu Corporation
P118	Comprehensive characterization of IVT mRNA products using ion pair reverse phase liquid chromatography coupled to high resolution accurate mass tandem mass spectrometry.	Robert	Ross	Thermo Fisher Scientific
P119	i-Motifs and C-rich DNA inhibit the processivity of the extension activity of human telomerase	Roberto	El-Khoury	McGill University

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P120	Molecular Dynamics simulations: how atomistic simulations can guide the synthetic efforts in ASO design	Rodrigo	Galindo-Murillo	Ionis Pharmaceuticals
P121	CRISPR-powered long noncoding RNA therapeutics for oncology	Rory	Johnson	University College Dublin
P122	Development of an ASO-based therapy targeting UBE3A for a patient with Dup15q Syndrome	Roxana	Redis	Charles River Laboratories
P123	Profiling Candidate ASOs for Target Gene Knock-Down: Potential Future Therapeutic Strategy for Neurodegenerative Diseases	Roxana	Redis	Charles River Laboratories
P124	ASO-RNA hybridization, cleavage, and activity at single-molecule resolution	Sabrina	Leslie	UBC
P125	Production of high-purity guide RNA by efficient and scalable self-templating ligation	Saikat	Bala	Beam Therapeutics
P126	Diverse panel of chemically-modified oligonucleotides show differential silencing activity in brain tumors and normal brain cells	Samantha	Sarli	RNA Therapeutics Institute
P127	Peptide-based siRNA and mRNA Polyplexes Enable Extrahepatic Targeting Of Diverse Pathologies	Samuel	Wickline	Altamira Therapeutics, Inc.
P128	A Novel ASO Shows Promise in Treating CMT2S: preclinical data	Sandra	Smieszek	Vanda Pharmaceuticals Inc.
P129	Potential Treatment for CMT2S caused by IGHMBP2 cryptic splice variant, with ASO based therapeutic	Sandra	Smieszek	Vanda Pharmaceuticals Inc.
P130	Development and functional analysis of photocaged RNA agonists for spatiotemporal control of RIG-I activation	Sandra	Zeidler	University Hospital Bonn
P131	eIF4E, as an oligonucleotide therapeutic target for pediatric drug-resistant epilepsy	Sang Min	Park	Sovargen Co., Ltd.

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P132	MAPT targeting di-siRNA inhibits the progression of Alzheimer's Disease	Sarah	Davis	UMass Chan Medical School
P133	Efficient exon 53 skipping of the human dystrophin transcript in a mouse model for Duchenne muscular dystrophy	Sarah	Engelbeen	Leiden University Medical Center
P134	Synthesis, Structure, and Biological Evaluation of siRNAs Containing Novel 2'-Fluoro Pyridone Nucleotides	Saul	Martinez Montero	Aligos Therapeutics
P135	siRNAs Modified with Novel 3',4'-Seco Nucleotides: Synthesis and Position-dependent Effect on Biological Properties	Saul	Martinez Montero	Aligos Therapeutics
P136	POTENTIATION OF DIVERSE ANTISENSE OLIGO PLATFORMS USING FDA-APPROVED AGENTS	Scott	Bittner	Carlson College of Veterinary Medicine, Oregon State University
P137	Switchable Small Nucleic Acid-Based Inhibitors for Controlling CRISPR-Cas9 Activity	Seth	Eddington	Southern Illinois University School Of Medicine
P138	Targeting Multiple OncomiRs for Glioma Therapy	Shipra	Malik	University of Connecticut
P139	Conjugation of a tri-antennary GalNAc ligand containing phosphorodithioates	Sophie	Schöllkopf	Silence Therapeutics
P140	Production of DNA decoy catalyzed with microRNA only in diseased cells	Soshu	Yasuda	The University of Tokyo
P141	In vitro selection of L-DNA aptamers that can inhibit microRNA biogenesis	Sougata	Dey	Texas A&M University
P142	Multi-targeting IO SeekR RNA oligo therapeutics	Spyro	Mousses	Oligon Inc
P143	Shorter development timelines via better analytics? Why democratize high-throughput automated Characterization of Oligonucleotide Therapeutics by Mass Spectrometry?	Stephen	Cypes	Protein Metrics Inc.

18th Annual Meeting of the Oligonucleotide Therapeutics Society

POSTER INDEX

P144 - V	At last we can realize the promise of SELEX. Laboratory in vitro evolution (LIVE) of Artificially Expanded Genetic Information Systems.	Steven	Benner	Firebird Biomolecular Sciences LLC
P145	A novel double-stranded structure of oligonucleotide improves silencing efficacy and mitigates CNS toxicity via intracerebroventricular administration	Su Su	Lei Mon	Tokyo Medical and Dental University
P146	Reduction of phosphorothioate in the gap by the use of 5'-cyclopropylene DNA (5'-CP)	Tadashi	Umemoto	Luxna Biotech
P147	Development and evaluation of a novel platform in oligonucleotide therapeutics based on divalent PEG linker conjugation	Tahia	Taufiq	Graduate School of Pharmaceutical Sciences, Osaka University
P148	Synthesis and property of oligonucleotides modified with amide-linked dinucleotides containing a 3',4'-bridged nucleic acid	Taiki	Akino	Graduate School of Pharmaceutical Sciences, Osaka University
P149	DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes and macrophage and microglia in vivo	Takanori	Yokota	Department of Neurology, Tokyo Medical and Dental University
P150	Chemical modifications in gap mitigate late-onset neurotoxicity of gapmer antisense oligonucleotide	Takayuki	Kuroda	Grad School of Medical & Dental Sciences, Tokyo Medical and Dental University
P151	Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy	Tiberiu	Stan	Leiden University Medical Centre
P152	Triblock Heterochiral Oligonucleotide Nanotechnology for Protection Against Exonuclease-mediated Degradation	Tracy	Mallette	University of New Mexico
P153	Strategic Optimization of siRNA Chemistry for Safe and Enhanced Silencing of Placental sFLT1	Vignesh Naraya	Hariharan	UMass Chan Medical School
P154	Lactobionic acid and N-Acetylgalactosamine-conjugated Peptide Nucleic Acids for in vivo targeting of hepatocytes	Vikas	Kumar	Department of Pharmaceutical Science, University of Connecticut
P155	Design, Synthesis, and Characterization of Phosphate Mimics for RNAi Activity of Conjugated siRNAs	Vivek	Rajwanshi	Aligos Therapeutics, Inc.

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P156	First Synthesis of Novel Deuterated siRNAs for Anti-HBV Activity	Vivek	Rajwanshi	Aligos Therapeutics, Inc.
P157	Development of a Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy	Xiang	Li	Entrada Therapeutics
P158	An Aptamer Targeting Transferrin Receptor for Drug Delivery	Xirui	Song	Duke University
P159	A Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Myotonic Dystrophy Type 1	Xiulong	Shen	Entrada Therapeutics
P160	The oligonucleotide therapeutics platform at Evotec: fully integrated RNA drug discovery	Yalda	Sedaghat	Evotec SE
P161	Positively charged guanine nucleobase to suppress self-duplex formation and improve PNA invasion efficiency.	Yuichiro	Aiba	Nagoya University
P162	Targeting regRNAs with oligonucleotides to treat OTC deficiency	Yun Joon	Jung	CAMP4 Theapeutics
P163	Development of antagonist aptamers to interleukin-6 receptor	Yuuya	Kasahara	National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
P164	Fatty acid and cell-penetrating motif conjugation for efficient intracellular delivery of antisense oligonucleotides	Yuya	Tanaka	Graduate School of Pharmaceutical Sciences, Osaka University
P165	Small interfering RNA-mediated allele-selective silencing of murine endothelial von Willebrand factor in vitro and in vivo	Yvonne	Jongejan	Leiden University Medical Center
P166	Domain Skipping in Nebulin as a Novel Therapy for Nemaline Myopathy	Zachary	Coulson	The Hospital for Sick Children
P167	Platform-based Delivery of Synthetic Oligonucleotides for Oncology Applications	Zdravka	Medarova	TransCode Therapeutics

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P168	In Vivo Modular Prime Editing via Non-viral Delivery	Zexiang	Chen	UMass Chan Medical School
P169	Aggregate repeat mutation C9ORF72 RNA is amenable to siRNA knockdown	Zack	Kennedy	UMass Chan Medical School
P170	Meta-Stable Nucleic Acid Junction For Multivalent Delivery of Therapeutics	Mawa	Ben Haj Salah	City of Hope
P171-V	Intracellular LBPA distribution and extracellular vesicle recycling define antisense oligonucleotide activity in tumour cells.	Alexander	Kapustin	AstraZeneca
P172-V	The Collection and Long-Term Preservation of Aptamer Sequence information in a Publicly Available Database	Ali	Askari	The University of Texas at Austin
P173-V	Modulation of Igf1 splicing towards mechano growth factor isoform by antisense oligonucleotide-mediated exon inclusion	Alper	Yavas	Leiden University Medical Center
P174-V	WITHDRAWN			
P175-V	WITHDRAWN			
P176-V	Optimer ligands provide versatile therapeutic strategies for novel disease biomarkers and increased therapeutic efficacy	Edward	Barnes	Aptamer Group
P177-V	ASP210 effectively reduces the leukemic burden in JAXTM mice by up to 99.1% within 10 days	Filip	Razga	Faculty of Medicine Comenius University
P178-V	Development of a GalNAc-asiRNA for Treatment of NASH with Fibrosis	June	Park	OliX Pharmaceuticals
P179-V	Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy	Kamila	Butowska	University of Pennsylvania

**18th Annual Meeting of the Oligonucleotide Therapeutics Society
POSTER INDEX**

P180-V	Development of splice-switching oligonucleotides (SSOs) that control the tumor suppressor REST	Keishiro	Mishima	Graduate School of Pharmaceutical Sciences, Osaka University
P181-V	Chemical modification patterns for microRNA therapeutic mimics: a structure-activity relationship (SAR) case-study on miR-200c.	Marion	Garreau	AstraZeneca
P182-V	QR-1011 restores splicing of multiple severe Stargardt disease type 1-causing splice site variants in ABCA4	Melita	Kaltak	ProQR Therapeutics
P183-V	Modulation of TNPO3 gene expression in Limb-Girdle Muscular Dystrophy D2	Paola	Dalگو	University Técnica Particular de Loja, Ecuador
P184-V	Suppression of an Oncogenic Androgen Receptor Splicing Variant Using Peptide-Morpholino Oligomer Conjugates	Rudy	Juliano	Initos Pharmaceuticals LLC
P185-V	Development of a novel cell-penetrating asymmetric siRNA platform for neurological disease treatment	Seong-Wook	Kim	OliX Pharmaceuticals
P186-V	Therapeutic Oligonucleotides for Primary Ciliary Dyskinesia	Silvia	Kreda	The University of North Carolina at Chapel Hill
P187-V	FORCETM platform for targeted delivery of oligonucleotide therapeutics in muscle diseases	Stefano	Zanotti	Dyne Therapeutics
P188-V	Therapeutic development of cell-penetrating asymmetric siRNA targeting the inflammatory pathway in advanced age-related macular degeneration	Sungmi	Park	OliX Pharmaceuticals, Inc.
P189-V	A novel antisense oligonucleotide targeting DUX4 strongly prevents motor function decline in a facioscapulohumeral muscular dystrophy (FSHD) model ACTA1-MCM/FLExDUX4 mice.	Tetsuhiro	Kakimoto	Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
P190-V	ASP210 – A potent oligonucleotide-based inhibitor against TKI-resistant CML cells	Veronika	Nemethova	Faculty of Medicine Comenius University
P191-V	WITHDRAWN			